-

11:57:38 PM

SLGL Stock News

SLGL - Sol-Gel Technologies Ltd

05/12/23 7:00 AM

Nasdaq : SLGL

earnings

Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Positive trends continue for TWYNEO ® and EPSOLAY ® with recurrent prescriber base s at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Phase 1 trial for SGT-210

RHEA-AI

neutral

03/20/23 7:00 AM

Nasdaq : SLGL

conferences

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced that it will present at H.C. Wainwright’s Autoimmune &

RHEA-AI

neutral

03/10/23 7:00 AM

Nasdaq : SLGL

earnings

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

Recent acquisition of Phase 3-ready SGT-610 ( p atidegib ) , an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome A Phase 3 study of SGT-610 is expected to initiate in the second half of 2023,

RHEA-AI

positive

01/27/23 7:29 AM

Nasdaq : SLGL

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY ® and TWYNEO ®, two innovative dermatology products that were launched in the U.S. by partner Galderma during 2022,

RHEA-AI

neutral

01/27/23 7:00 AM

Nasdaq : SLGL

acquisitionclinical trial

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDA Phase 3 study expected to initiate in the second half of 2023, with results expected by the end of 2025

RHEA-AI

positive

11/10/22 4:00 AM

Nasdaq : SLGL

earnings

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology

RHEA-AI

positive

10/03/22 8:00 AM

Nasdaq : SLGL

management

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today the appointment of

RHEA-AI

very positive

08/04/22 6:00 AM

Nasdaq : SLGL

earnings

Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

P rescription volumes to date indicate strong uptake, similar to successful dermatology launches Sol-Gel r eceives $3.5 million milestone payment from commercial partner Galderma Holding SA (“Galderma”) for FDA approval of EPSOLAY Sol-Gel’s cash runway expected to extend through the end of 2023

RHEA-AI

very positive

06/01/22 8:00 AM

Nasdaq : SLGL

conferences

Sol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced that Chief

RHEA-AI

neutral

05/17/22 7:00 AM

Nasdaq : SLGL

conferences

Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced that that the

RHEA-AI

neutral

SLGL Data

IndustryMedicinal and Botanical Manufacturing
Websitewww.sol-gel.com
CeoAlon Seri-Levy
Security nameSol-Gel Technologies Ltd
Issue typecs
SectorManufacturing
Sic code2834
Employees55
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Medicinal and Botanical Manufacturing
AddressWeizmann Science Park
StateNess Ziona
City7 Golda Meir
Zip7403650
CountryIsrael
Phone97289313433

About Sol-Gel Technologies Ltd

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of inflammatory lesions of rosacea. The Company's pipeline also includes SGT-210 (erlotinib gel), under investigation for the treatment of palmoplantar keratoderma, and three pre-clinical assets - erlotinib, tapinarof and roflumilast - currently being tested for various pharmaceutical indications.